68Ga Trivehexin PET/CT in a Breast Carcinoma Patient With Distant Metastasis: Edge Over 18F-FDG PET/CT?
FDG PET CT has limitations in breast cancer due to its low tracer uptake in Grade 1 and 2 tumors, estrogen receptor positivity, lobular histology, and osteoblastic skeletal metastases.
APA
Mohite A, Luthra K, et al. (2026). 68Ga Trivehexin PET/CT in a Breast Carcinoma Patient With Distant Metastasis: Edge Over 18F-FDG PET/CT?. Clinical nuclear medicine. https://doi.org/10.1097/RLU.0000000000006178
MLA
Mohite A, et al.. "68Ga Trivehexin PET/CT in a Breast Carcinoma Patient With Distant Metastasis: Edge Over 18F-FDG PET/CT?." Clinical nuclear medicine, 2026.
PMID
41649854
Abstract
FDG PET CT has limitations in breast cancer due to its low tracer uptake in Grade 1 and 2 tumors, estrogen receptor positivity, lobular histology, and osteoblastic skeletal metastases. Trivehexin PET targets αvβ6 integrin, which is relatively specific for epithelial cancer cells. We present a case of a 67-year-old woman with recently diagnosed metastatic breast cancer. Trivehexin PET not only showed lesions with a higher target-to-background ratio compared with FDG PET but also depicted additional metastatic sites.